Method for the in vivo negative regulation of amyloid protein in an animal, including a human being and for the treatment and / or prevention and / or amelioration of alzheimer's disease or other diseases and conditions characterized by amyloid deposits, analog of an amyloidogenic polypeptide , immunogenic composition, nucleic acid fragment, vector, transformed cell, composition to induce the production of antibodies against an amyloidogenic polypeptide, stable cell line, methods for the preparation of a cell, for the identification of a modified amyloidogenic polypeptide, and for preparation of an immunogenic composition, use of an amyloidogenic polypeptide or a subsequence thereof, and use of an analog of an amyloidogenic polypeptide

摘要

"METHODS FOR THE NEGATIVE IN VIVO REGULATION OF AMYLOID PROTEIN IN AN ANIMAL, INCLUDING A HUMAN BEING, AND FOR THE TREATMENT AND / OR PREVENTION AND / OR IMPROVEMENT OF ALZHEIMER'S DISEASE OR OTHER DISEASES AND CONDITIONS CHARACTERIZED BY A LOT OF PEOPLE, ALWAYS CHARACTERIZED BY LOS ANGELES. polypeptide amyloidogenic, immunogenic composition, Nucleic acid fragment, VECTOR, transformed cell, cOMPOSITION TO iNDUCE A aNTIBODY pRODUCTION AGAINST A polypeptide amyloidogenic, PEDIGREE cELL stable methods for the preparation of a cell, for identifying a polypeptide amyloidogenic mODIFIED, AND FOR THE PREPARATION OF AN IMMUNOGENEOUS COMPOSITION, USE OF AN AMYLOIDOGENIC POLYPEPTIDE OR SUBSEQUENCE OF THE SAME, AND USE OF AN ANALOG OF AN AMYLOIDOGENIC POLYPEPTIDE. " New methods are presented to combat diseases characterized by amyloid deposition. The methods generally rely on immunization against amyloidogenic proteins (proteins that contribute to the formation of amyloid) such as beta amyloid (A 225). Immunization is preferably carried out by the administration of autologous amyloidogenic polypeptide analogs, said analogues being able to induce the production of antibodies against autologous amyloidogenic polypeptides. Especially preferred as an immunogen is A 225 which has been modified by the introduction of a single or a few heterologous, immunodominant and heterogeneous T cell epitopes while substantially preserving the majority of AB's B cell epitopes. Also shown are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for vaccination. Such methods and means include methods for the identification of useful immunogenic analogues of amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as fragments of nucleic acid, vectors, transformed cells, polypeptides and pharmaceutical formulations.